Active Ingredient : Semaglutide, a GLP-1 receptor agonist Mechanism of Action : According to FDA prescribing information, semaglutide works by: Increasing glucose-dependent insulin secretion Decreasing glucagon secretion Slowing gastric emptying Acting on centers in the brain that regulate appetite Clinical Trial Evidence - STEP Program : According to published data from the STEP 1 trial (New England Journal of Medicine, 2021): Study Design : 68-week randomized, double-blind, placebo-controlled trial 1,961 adults without diabetes Inclusion: BMI 30 or 27 with weight-related conditions Intervention: Once-weekly subcutaneous semaglutide 2.4 mg Lifestyle: 500-calorie deficit diet plus 150 minutes/week physical activity Primary Results : Semaglutide group: Average 14.9% body weight loss (approximately 33 lbs for 220 lb individual) Placebo group: Average 2.4% body weight loss (approximately 5 lbs for 220 lb individual) Difference: 12.4 percentage points (p 3 pounds/week associated with higher risk
With a verified fill volume of 3 mL and precise component concentrations, it meets the exacting standards demanded by modern peptide research laboratories
Clinical trials demonstrate average A1c reductions of 1.9-2.4% from baseline, with many patients achieving target levels below 7%
Similar to BCBS, virtual visits provide patients access to personalized nutrition plans and resources
Description This research blend combines two growth hormoneaxis peptides in a single lyophilized vial: CJC-1295 without DAC (Mod GRF 1-29) and ipamorelin
